INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Risk Mitigation For Late-Stage Clinical Assets

  Leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering.

• Fast-Track Innovation, Address CMC Challenges In Expedited Pathways

  Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

• Shedding Light On Photo-Stability Forced Degradation

  Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.

• 4 Things To Consider In Pharmaceutical Labeling

  Pharmaceutical labeling demands precision. Examine key considerations for ensuring accuracy and efficiency in your process, from robust control systems to diverse printing options.

• Global Complexity Demands Local Resilience

  8/31/2026

  With integrated capabilities spanning early development through commercial manufacturing, our U.S. network helps customers build greater supply chain resilience, navigate uncertainty, and create a more reliable path to market.

• Global Strategies For Resilience And Redundancy In Cell Culture Media Supply

  7/17/2025

  Ensure your cell culture media supply remains uninterrupted. Explore proactive strategies for global manufacturing equivalency and consistent media delivery.

• The Team For Your Package Design Needs

  8/16/2025

  Our dedicated team of in-house design specialists deliver insightful packaging design and practical knowledge to deliver differentiated and cost-effective packaging solutions.

• The Future Of RNA Manufacturing Starts With Raw Material Innovation

  2/11/2026

  Amid the mRNA and oligonucleotide therapeutic boom, sponsors and manufacturers are exploring how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

• Integrated Single-Site CDMO Model

  3/16/2026

  A single‑site model reduces handoff risks, speeds timelines, strengthens quality oversight, and unifies development and manufacturing to improve reliability and execution efficiency.